On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per share range between $3.40 to $3.50; Revenue consensus $2.67B. Following the consummation of the transaction and assuming the transaction closes late in the second quarter 2025, Globus Medical anticipates 2025 net sales of $2.8B to $2.9B and fully diluted non-GAAP earnings per share range between $3.10 to $3.40. Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical to acquire Nevro for $5.85 per share
- Dentsply Sirona appoints Barber, Scavilla as new board members
- Globus Medical price target raised to $101 from $92 at Canaccord
- Globus Medical upgraded to Neutral from Underperform at BofA
- Closing Bell Movers: Penguin Solutions up 16% on earnings beat
Questions or Comments about the article? Write to editor@tipranks.com